WP
BNTC icon

Woodline Partners’s Benitec Biopharma BNTC Stock Holding History

Woodline Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,704
Closed -$1.36M – 1043
2025
Q4 		$1.36M Buy
+100,704
New +$1.39M 0.01% 812

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Woodline Partners's BNTC Position: Q1 2026 in Review

Woodline Partners sold out of Benitec Biopharma (BNTC) in Q1 2026, closing a stake of 100,704 shares — an estimated $1.36M sold.

Woodline Partners first reported a position in BNTC in Q4 2025 and held it in 1 quarter. The position peaked at $1.36M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Woodline Partners reported no remaining Benitec Biopharma position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 100,704 Benitec Biopharma shares in Q1 2026, an estimated $1.36M.
  • Woodline Partners first reported a position in Benitec Biopharma in Q4 2025 and held it in 1 quarter.
  • Woodline Partners's Benitec Biopharma position peaked at $1.36M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.